Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + capecitabine with radiotherapy in non-resectable locally advanced pancreatic cancer
2006-002992-42Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and capecitabine in pancreatic cancer (PC) and Pancreatic carcinoma (PC), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Overall survival at 1 year. Started Jul 2007; status: active.
02
Drugs
bevacizumabcapecitabine
03
Conditions
pancreatic cancer (PC)Pancreatic carcinoma (PC)
Beyond the preview
Go deeper on 2006-002992-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002992-42.